The medtech giant designed Tecnis PureSee IOL to deliver clarity of vision for patients. It says that 97% of patients report no very bothersome visual disturbances.
J&J plans to make Tecnis PureSee available for U.S. patients later this year.
The company said approval makes the system the first and only extended depth of focus (EDOF) IOL with no warning on loss of contrast sensitivity available in the U.S. It helps patients experience visual clarity and confidence with an extended range of vision through a single procedure.
J&J built the IOL on its Tecnis platform, combining optics with proprietary material. It mitigates the effects of presbyopia by providing extended depth of focus. This enables strong distance and intermediate vision, with some near vision. The company said it reduces patient reliance on glasses following surgery.
Tecnis PureSee has approvals around the world, already treating nearly half a million eyes worldwide, the company said. It launched the offering in EMEA in 2024. The IOL expands J&J’s surgical vision portfolio, which includes a range of offerings, including the Tecnis Odyssey IOL rolled out in late 2024.
(IOLs are a hot topic of late after Alcon’s failed acquisition of IOL developer Staar Surgical. Read more here.)
Peter Menziuso, company group chair, Vision, Johnson & Johnson, said:
“Today marks an exciting milestone for people living with cataracts. The approval of the Tecnis PureSee IOL gives surgeons an important new lens option, reflecting our deep commitment to innovation that delivers high patient satisfaction and supports vision solutions tailored to individual lifestyle needs. Cataract surgery is often a once-in-a-lifetime opportunity for patients to restore and enhance their vision. With the addition of Tecnis PureSee IOL to our portfolio, we can help even more patients regain not just sight, but the quality, range, and visual performance they expect from a Johnson & Johnson product.”
